9,166
Total Claims
$2.2M
Drug Cost
1,068
Beneficiaries
$2,045
Cost/Patient
Peer Comparison vs. 18,720 Cardiology providers
+34%
Cost per patient vs peers
$2,045 vs $1,524 avg
Brand vs Generic
100% generic
Brand: 0 claims · $0
Generic: 7,450 claims · $244K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Empagliflozin | 387 | $540K |
| Apixaban | 306 | $420K |
| Rivaroxaban | 221 | $318K |
| Sacubitril/Valsartan | 232 | $240K |
| Evolocumab | 164 | $178K |
| Alirocumab | 86 | $94K |
| Ezetimibe | 540 | $28K |
| Evolocumab | 20 | $21K |
| Valsartan/Hydrochlorothiazide | 360 | $19K |
| Bempedoic Acid/Ezetimibe | 19 | $17K |
| Dabigatran Etexilate Mesylate | 34 | $14K |
| Bempedoic Acid | 11 | $14K |
| Rosuvastatin Calcium | 440 | $11K |
| Potassium Chloride | 271 | $10K |
| Isosorbide Dinitrate | 77 | $9,644 |
Prescribing Profile
78
Unique Drugs
$1.5M
Patient Profile
78
Avg Age
47%
Female
1.59
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data